A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Ceritinib Impurity 13 - Request Quote

Picture of Ceritinib Impurity 13

Ceritinib Impurity 13

SZ CAT No:SZ-C136018
CAS No
NA
Mol.F.
C22H26N2O3 : HCl
Mol.Wt.
366.5 : 36.5
Inv. Status
Synthesis on demand
Rel. CAS No1941226-40-9 (free base)

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Ceritinib Impurity 13 is chemically 1-Benzyl-4-(5-isopropoxy-2-methyl-4-nitrophenyl)-1,2,3,6-tetrahydropyridine hydrochloride. Ceritinib Impurity 13 is supplied with detailed characterization data compliant with regulatory guideline. Ceritinib Impurity 13 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Ceritinib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Ceritinib Impurity 13

Purchase Ceritinib Impurity 13

Ceritinib Impurity 13 suppliers

Ceritinib Impurity 13 manufacturers

Ceritinib Impurity 13 price

Order Ceritinib Impurity 13

Enquire Ceritinib Impurity 13

Ceritinib Impurity 13 cost

Ceritinib Impurity 13 Supplier

Ceritinib Impurity 13 Distributor

Ceritinib Impurity 13 for Method Validation

Ceritinib Reference Standard

Ceritinib Impurity 13 for ANDA Filing

Ceritinib Impurity 13 for Forced Degradation Studies

Ceritinib Impurity 13 Identification Standards

Ceritinib Impurity 13 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,